ロード中...
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
INTRODUCTION: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis o...
保存先:
| 出版年: | Expert Opin Orphan Drugs |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577425/ https://ncbi.nlm.nih.gov/pubmed/33094033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2019.1664900 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|